RxDoctor Payments Data

Alexander Williams, MD

Endocrinology, Diabetes & Metabolism · Clearwater, FLNPI 1073977310

Payments from drug & device makers

$18,706in general payments, 2019–2025

Across 349 payments — averaging $53.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • Neurocrine Biosciences, Inc.$3K
  • Novo Nordisk$3K
  • Kyowa Kirin, Inc.$1K
  • Lilly USA, LLC$734
  • Amgen$667
  • plus $5K from 36 others

What the payments were for

  • Consulting fees$10,16554%
  • Travel & lodging$5353%
  • Food & beverage$7,96343%
  • Education$430%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,706 in reported general payments places this provider in the 75th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$83,245
Medicare patients
285
Services billed
1,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide179$256,549
MounjaroTirzepatide164$237,208
JardianceEmpagliflozin143$182,096
RybelsusSemaglutide38$77,189
FarxigaDapagliflozin Propanediol60$72,857
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog39$48,719
TymlosAbaloparatide17$45,343
TrulicityDulaglutide26$36,399
Synjardy XrEmpagliflozin/Metformin Hcl21$34,580
Tresiba Flextouch U-200Insulin Degludec26$28,089
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$26,107
Tresiba Flextouch U-100Insulin Degludec44$25,563
JanuviaSitagliptin Phosphate19$24,185
Fiasp FlextouchInsulin Aspart (Niacinamide)21$23,141
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$8,681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$2,684$338,208241 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$734$279,102208 claims
Boehringer IngelheimJardiance, Synjardy Xr$321$216,676164 claims
AstraZenecaFarxiga$4,648$72,85760 claims
Radius Health, Inc.Tymlos$191$45,34317 claims
AbbVieSynthroid$174$6,46059 claims
Sanofi-aventis U.S. LLCLantus$323$4,06818 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$152$3,320296 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →